Breast Biopsy Market by Product (Assay Kits, Biopsy Needles, Biopsy Tables), Type (Liquid Breast Biopsy, Needle Breast Biopsy, Open Surgical Breast Biopsy), Guidance, Application - Global Forecast 2023-2030

Breast Biopsy Market by Product (Assay Kits, Biopsy Needles, Biopsy Tables), Type (Liquid Breast Biopsy, Needle Breast Biopsy, Open Surgical Breast Biopsy), Guidance, Application - Global Forecast 2023-2030


The Breast Biopsy Market is projected to reach USD 1,872.86 million by 2030 from USD 924.20 million in 2022, at a CAGR of 9.23% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Breast Biopsy Market.
  • Based on Product, market is studied across Assay Kits, Biopsy Needles, Biopsy Tables, Guidance Systems, Liquid Biopsy Instruments, and Localization Wires. The Localization Wires is projected to witness significant market share during forecast period.
  • Based on Type, market is studied across Liquid Breast Biopsy, Needle Breast Biopsy, and Open Surgical Breast Biopsy. The Liquid Breast Biopsy is further studied across Circulating Tumor Cells and Circulating Tumor DNA. The Needle Breast Biopsy is further studied across Core Needle Biopsy, Fine Needle Aspiration Biopsy, and Vacuum-Assisted Biopsy. The Open Surgical Breast Biopsy is further studied across Excisional and Incisional. The Needle Breast Biopsy is projected to witness significant market share during forecast period.
  • Based on Guidance, market is studied across Image-Guided Biopsy and Liquid Biopsy. The Image-Guided Biopsy is further studied across Mammography-Guided Stereotactic Biopsy, MRI Guided Biopsy, and Ultrasound-Guided Biopsy. The Liquid Biopsy is further studied across Microarray-Based Biopsy, NGS-Based Biopsy, and PCR-Based Biopsy. The Image-Guided Biopsy is projected to witness significant market share during forecast period.
  • Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring. The Early Cancer Screening is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Breast Biopsy Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Breast Biopsy Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Breast Biopsy Market, highlighting leading vendors and their innovative profiles. These include Argon Medical, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., Cook Group Incorporated, CooperSurgical, Inc., F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., FUJIFILM Corporation, GE HealthCare, Guardant Health, Halma plc, Hologic, Inc., Illumina, Inc., INRAD, Inc., Iskus Health Ltd., Johnson & Johnson Services, Inc., Leica Biosystems Nussloch GmbH, Medtronic PLC, Merit Medical Systems, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., TransMed7, LLC, and Trivitron Healthcare.

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Breast Biopsy Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Breast Biopsy Market?
  3. What is the competitive strategic window for identifying opportunities in the Breast Biopsy Market?
  4. What are the latest technology trends and regulatory frameworks in the Breast Biopsy Market?
  5. What is the market share of the leading vendors in the Breast Biopsy Market?
  6. Which modes and strategic moves are suitable for entering the Breast Biopsy Market?


Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Breast Biopsy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of breast cancer worldwide
5.1.1.2. Government initiative for awareness and treatment of breast cancer
5.1.1.3. Shifting preferences for early detection and screening for breast cancer
5.1.2. Restraints
5.1.2.1. High-cost and time consuming procedure
5.1.3. Opportunities
5.1.3.1. Emergence of liquid biopsy and promising clinical trials
5.1.3.2. Increasing investments and funding for R&D of breast cancer treatment
5.1.4. Challenges
5.1.4.1. Possibilities of infection associated with biopsy needles
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Breast Biopsy Market, by Product
6.1. Introduction
6.2. Assay Kits
6.3. Biopsy Needles
6.4. Biopsy Tables
6.5. Guidance Systems
6.6. Liquid Biopsy Instruments
6.7. Localization Wires
7. Breast Biopsy Market, by Type
7.1. Introduction
7.2. Liquid Breast Biopsy
7.3.1. Circulating Tumor Cells
7.3.2. Circulating Tumor DNA
7.3. Needle Breast Biopsy
7.4.1. Core Needle Biopsy
7.4.2. Fine Needle Aspiration Biopsy
7.4.3. Vacuum-Assisted Biopsy
7.4. Open Surgical Breast Biopsy
7.5.1. Excisional
7.5.2. Incisional
8. Breast Biopsy Market, by Guidance
8.1. Introduction
8.2. Image-Guided Biopsy
8.3.1. Mammography-Guided Stereotactic Biopsy
8.3.2. MRI Guided Biopsy
8.3.3. Ultrasound-Guided Biopsy
8.3. Liquid Biopsy
8.4.1. Microarray-Based Biopsy
8.4.2. NGS-Based Biopsy
8.4.3. PCR-Based Biopsy
9. Breast Biopsy Market, by Application
9.1. Introduction
9.2. Early Cancer Screening
9.3. Recurrence Monitoring
9.4. Therapy Selection
9.5. Treatment Monitoring
10. Americas Breast Biopsy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Breast Biopsy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Breast Biopsy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
13.3.2. New Product Launch & Enhancement
13.3.2.1. TransMed7, LLC Announces First Clinical Use of SpeedBird Breast Biopsy Devices for Commercial Launch
13.3.3. Award, Recognition, & Expansion
13.3.3.1. Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for Menarini Group’s ORSERDU for the Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Argon Medical
14.1.2. Becton, Dickinson, and Company
14.1.3. Bio-Rad Laboratories, Inc
14.1.4. Biocept, Inc.
14.1.5. Cook Group Incorporated
14.1.6. CooperSurgical, Inc.
14.1.7. F. Hoffmann-La Roche Ltd.
14.1.8. Fluxion Biosciences Inc.
14.1.9. FUJIFILM Corporation
14.1.10. GE HealthCare
14.1.11. Guardant Health
14.1.12. Halma plc
14.1.13. Hologic, Inc.
14.1.14. Illumina, Inc.
14.1.15. INRAD, Inc.
14.1.16. Iskus Health Ltd.
14.1.17. Johnson & Johnson Services, Inc.
14.1.18. Leica Biosystems Nussloch GmbH
14.1.19. Medtronic PLC
14.1.20. Merit Medical Systems
14.1.21. Siemens Healthineers
14.1.22. Sysmex Corporation
14.1.23. Thermo Fisher Scientific Inc.
14.1.24. TransMed7, LLC
14.1.25. Trivitron Healthcare
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings